# Genome-wide meta-analysis of over 29,000 people with epilepsy reveals 26 loci and subtype-specific genetic architecture

## International League Against Epilepsy Consortium on Complex Epilepsies

# Supplementary Material

### Supplementary Tables

Supplementary table 1. Overview of novel cohorts, genotyping array and sample sizes. HK: Hong Kong; JPN: Japan.

Cohort	Genotyping platform	Ethnicity	Phenotype	Cases
	•		All epilepsy	11544
			GGE	3153
		European	Focal	4523
			Unclassified	3868
			Control	13121
			All epilepsy	474
			GGE	91
		European: Finnish	Focal	314
			Unclassified	-
			Control	986
			All epilepsy	612
			GGE	276
Epi25	Illumina Infinium GSA	African	Focal	230
			Unclassified	106
			Control	3838
			All epilepsy	839
		Asian: HK	GGE	55
			Focal	639
			Unclassified	145
			Control	594
			All epilepsy	256
			GGE	63
		Asian: JPN	Focal	4
			Unclassified	189
			Control	211
			All epilepsy	201
Norwegian GenEpa	Human610-Quadv1	European	Focal	201
Conipa			Control	-
			All epilepsy	231
Swiss GenEpa	Illumina Human610- Quadv1	European	Focal	231
			Control	259

Jansen Pharmaceuticals	Illumina 1M		All epilepsy	410
		European	Focal	410
			Control	3016
	Illumina Human CNV 370 duo		All epilepsy	165
Austrian GenEpa		European	Focal	165
			Control	337

Supplementary table 2. Overview of number of cases and controls, stratified by phenotype and ethnicity.

Phenotype	Sub-phenotype description	n	EUR	ASI	AFR
GGE	Generalized Epilepsy, not otherwise specified, with spike and wave EEG	3352	3024	44	284
	Childhood Absence Epilepsy (CAE)	1072	1049	6	17
	Juvenile Absence Epilepsy (JAE)	671	662	4	5
	Juvenile Myoclonic Epilepsy (JME)	1813	1732	61	20
	GTCS only, with spike and wave EEG	499	485	3	11
	Subtotal	7407	6952	118	337
Focal	Focal Epilepsy, not otherwise specified	3981	3688	140	153
	Focal Epilepsy, documented lesion negative	6367	5778	466	123
	Focal Epilepsy, documented hippocampal sclerosis (HS)	1375	1260	107	8
	Focal Epilepsy, documented lesion other than HS	4661	4213	416	32
	Subtotal	16384	14939	1129	316
Unclassified	Epilepsy, not otherwise specified	6153	5668	379	106
	Cases	29944	27559	1626	759
	Controls	52538	42436	3680	6422
	Total subjects	82482	69995	5306	7181

Supplementary table 3. Summary of all genome-wide significant loci including genomic position and independent significant SNPs. We defined the locus position as the region encompassing all SNPs with P<10-4 that were in LD ( $R^2>0.2$ ) with the lead SNP.

Phenotype	Locus name	Locus position (hg19)	Lead SNP	Number of independent significant SNPs	Independent significant SNPs
All epilepsy	2p16.1	chr2:57917222-58505679	rs13032423	1	rs13032423
	2q24.3	chr2:166716305-167124221	rs59237858	2	rs59237858; rs1960242
	9q21.13	chr9:76297313-76625089	rs4744696	1	rs4744696
	10q24.32	chr10:103493226-103989812	rs3740422	1	rs3740422
GGE	1q43	chr1:237846053-237908911	rs876793	1	rs876793
	2p16.1	chr2:57917222-58756729	rs11688767	3	rs11688767; rs77876353; rs13416557
	2q12.1	chr2:104056769-104481325	rs62151809	1	rs62151809
	2q24.3	chr2:166818404-166994996	rs11890028	1	rs11890028
	2q32.2	chr2:191504467-191710069	rs6721964	1	rs6721964
	3p22.3	chr3:36218075-36345769	rs9861238	1	rs9861238

	3p21.31	chr3:50184538-50421081	rs739431	1	rs739431
	4p15.1	chr4:31107765-31204950	rs1463849	1	rs1463849
	5q22.3	chr5:113837198-114440966	rs4596374	1	rs4596374
	5q31.2	chr5:136459562-136684519	rs2905552	1	rs2905552
	6q22.33	chr6:128302874-128333682	rs13219424	1	rs13219424
	7p14.1	chr7:41334517-41411165	rs37276	1	rs37276
	9q21.32	chr9:86320233-86694759	rs2780103	1	rs2780103
	10q24.32	chr10:103493226-103989812	rs11191156	1	rs11191156
	12q13.13	chr12:52319584-52348259	rs114131287	2	rs4762030; rs10431492
	16p13.3	chr16:7285674-7442293	rs62014006	1	rs62014006
	17p13.1	chr17:8036060-8219478	rs2585398	1	rs2585398
	17q21.32	chr17:45938105-46554456	rs16955463	1	rs16955463
	19p13.3	chr19:2102543-2136680	rs75483641	1	rs75483641
	21q21.1	chr21:21655062-21719113	rs1487946	1	rs1487946
	21q22.1	chr21:32036541-32203274	rs7277479	1	rs7277479
	22q13.32	chr22:48615721-48639993	rs469999	1	rs469999
CAE	2p16.1	chr2:57942325-58484172	rs12185644	1	rs12185644
JME	4p12	chr4:46250605-46397617	rs17537141	1	rs17537141
	8q23.1	chr8:109733213-109922163	rs3019359	1	rs3019359
	16p11.2	chr16:30603521-31275374	rs1046276	1	rs1046276

Supplementary table 4. Results from ASSET pleiotropy analyses for the 4 all epilepsy loci. The associated phenotype/s in ASSET reflect the phenotypes driving the ASSET signal, which could be both GGE individually. \*Evidence for pleiotropy between GGE and Focal epilepsy.

SNP (Risk allele)	Chr.	Locus	P-value (GGE)	P-value (FE)	OR (ASSET)	P-value (ASSET)	Associated phenotype in ASSET
*rs60055328(C)	2	2q24.3	1.04e-7	9.62e-7	1.07	2.8e-10	GGE, FE
*rs4744696(G)	9	9q21.13	3.07e-7	8.63e-5	0.93	4.4e-8	GGE, FE
rs13032423(G)	2	2p16.1	2.88e-17	2.93e-3	0.85	8.9e-17	GGE only
rs3740422(G)	10	10q24.32	1.02e-13	4.07e-3	1.15	2.48e-12	GGE only

Supplementary table 5. Heritability enrichment of 26 functional categories, as assessed with LDAK heritability enrichment analyses. Statistical significance (in bold) is defined as P<0.05/26=0.0019.

Annotation	Share	SD	Expected	Enrichment	SD	Z-score	P-value
Coding_UCSC	0.069948	0.027717	0.016079	4.350169	1.723782	1.943499	0.051956
Conserved_LindbladToh	0.132451	0.042109	0.028542	4.640618	1.475346	2.467637	0.013601
CTCF_Hoffman	0.017421	0.041158	0.023919	0.728312	1.720706	0.157893	0.874541
DGF_ENCODE	0.166208	0.095467	0.138091	1.203615	0.691336	0.294524	0.768358
DHS_Trynka	0.139003	0.100726	0.167956	0.827614	0.599718	0.287445	0.773772

Enhancer_Andersson	-0.00046	0.018624	0.004432	-0.104203	4.202414	0.262754	0.79274
Enhancer_Hoffman	0.065675	0.041653	0.042964	1.528598	0.969479	0.545239	0.585589
FetalDHS_Trynka	0.124737	0.077198	0.085617	1.456925	0.901664	0.506758	0.612325
H3K27ac_Hnisz	0.466327	0.030543	0.393028	1.186496	0.077713	2.399804	0.016404
H3K27ac_PGC2	0.350543	0.056076	0.272914	1.284446	0.20547	1.384368	0.166246
H3K4me1_Trynka	0.578187	0.066915	0.428916	1.34802	0.156009	2.230769	0.025696
H3K4me3_Trynka	0.229663	0.052572	0.137162	1.674388	0.38328	1.759518	0.07849
H3K9ac_Trynka	0.253873	0.05353	0.129088	1.966671	0.414683	2.331108	0.019748
Intron_UCSC	0.45682	0.026361	0.394342	1.158437	0.066848	2.370108	0.017783
PromoterFlanking_Hoffman	0.021395	0.026356	0.008596	2.488946	3.066092	0.485617	0.627239
Promoter_UCSC	0.083972	0.035858	0.048118	1.74512	0.745213	0.999875	0.317371
Repressed_Hoffman	0.41399	0.06557	0.452761	0.914367	0.144823	0.591294	0.554323
SuperEnhancer_Hnisz	0.242302	0.019093	0.169819	1.42682	0.112434	3.796183	0.000147
TFBS_ENCODE	0.225196	0.07818	0.133056	1.692483	0.58757	1.178554	0.238576
Transcr_Hoffman	0.420967	0.057675	0.35335	1.191361	0.163225	1.172376	0.241046
TSS_Hoffman	0.046568	0.02996	0.018755	2.482921	1.5974	0.928334	0.353234
UTR_3_UCSC	0.013363	0.017055	0.011944	1.118787	1.427882	0.083191	0.9337
UTR_5_UCSC	0.02092	0.016217	0.005928	3.529243	2.735834	0.924487	0.355233
WeakEnhancer_Hoffman	-0.03501	0.039502	0.021357	-1.63943	1.849623	1.42701	0.153577
Super_Enhancer_Vahedi	0.029165	0.008124	0.021624	1.348773	0.375709	0.928306	0.353249
Typical_Enhancer_Vahedi	0.026998	0.011727	0.022194	1.216444	0.528371	0.409644	0.682067

Supplementary table 6. Estimation of inflation factor and the LD-score regression intercept stratified by phenotype.  $\lambda$ : genomic inflation factor,  $\lambda_{1000}$ : genomic inflation factor corrected for an equivalent study of 1000 cases and 1000 controls.

Phenotype	λ	λ1000	Mean χ2	LDSC intercept
All epilepsy	1.25	1.01	1.27	1.10
Focal epilepsy	1.17	1.01	1.17	1.10
GGE	1.26	1.02	1.35	1.04

Supplementary table 7. SNP-based heritabilities as calculated by LDAK, with the BLD-LADK model. Observed-scale heritability is calculated using effective-sample sizes, after which it was converted to liability-scale heritability using the same prevalence estimates as our previous GWAS.<sup>1</sup>

Phenotype	cases	controls	K: prevalence	Z	Observed- scale heritability	Liability scale heritability
All epilepsy	27559	42436	0.005	0.0145	0.3733	0.177 (0.155 - 0.199)
Focal epilepsy	14939	42436	0.003	0.0091	0.3733	0.160 (0.140 - 0.180)
GGE	6952	42436	0.002	0.0063	0.9955	0.395 (0.343 - 0.446)
JME	1728	37339	0.00035	0.0013	2.1135	0.635 (0.510 - 0.760)
JAE	662	37339	0.00015	0.0006	3.3528	0.900 (0.633 - 1.166)
CAE	1049	37339	0.00015	0.0006	3.0427	0.816 (0.638 - 0.995)
GTCSA	485	37339	0.0002	0.0008	1.7824	0.496 (0.140 - 0.853)
Focal HS	1260	37339	0.00075	0.0026	1.4020	0.472 (0.294 - 0.649)
Focal other lesion	4213	37339	0.00135	0.0044	0.6778	0.251 (0.188 - 0.313)
Focal non- lesional	5778	37339	0.0009	0.0031	0.2452	0.085 (0.046 -0.124)

Supplementary table 8. Top 20 drugs that are licensed for conditions other than epilepsy, but are predicted to be efficacious for GGE, and have published evidence of antiseizure efficacy from multiple published studies and in multiple animal models. We do not advise immediate use of these drugs for people with epilepsy, prior to any clinical trials. AUD: audiogenic; electro: maximal electroshock; Kin: kindling; PTZ: pentylenetetrazol. Drugs are listed in alphabetical order.

Drug	Current indication	Studies' PubMed IDs	Models
Aspirin	Pain; pyrexia; antiplatelet	11883156, 14671677, 16844276, 22765917, 28060522	Pilo, PTZ, Electro
Biperiden	Parkinson's disease	738231, 2858579	Electro, other
Captopril	Hypertension; chronic heart failure; diabetic nephropathy	2824310, 22107891, 25573423	PTZ, AUD, Other
Citalopram	Depression; panic disorder	21531632, 21962757, 22429158, 22578701	KA, PILO, PTZ
Dapsone	Leprosy; dermatitis herpetiformis	1817960, 7970237, 23729301	KA, Kin
Dextromethorphan	Pain; addiction; cough 1456842, 2079649, 2574061, 2666123, 2676564, 2806362, 3044591, 3374269, 3380326, 3768695, 8058587, 8094234, 8405092, 8856734, 9179861, 9187330, 10080248, 11182165, 12479976, 12586225, 15084442, 15723099		KA, PTZ, Electro, AUD, Kin, other
Diltiazem	Angina; hypertension	2272645, 7681002, 8152336, 22661180	KA, PTZ, Electro
Doxepin	Depression; pruritus	1456842, 19443935	PTZ, Electro, other
Fluoxetine	Depression; bulimia nervosa; obsessive- compulsive disorder	7999524, 8149989, 8384110, 8538363, 8816259, 9696406, 15680343, 16531634, 17215106, 23530452, 25754610	Electro, AUD, other
Isradipine	Hypertension	8118482, 9595291	Electro, AUD
Lovastatin	Hypercholesterolaemia	21224519, 23253428, 23352156	KA, AUD
Nicardipine	Angina; hypertension	7681002, 8152336, 8872866, 10608279, 11742591	KA, PTZ, Kin, other
Nifedipine	Angina; hypertension; Raynaud's phenomenon; premature labour	1628595, 1698518, 1747472, 1865996, 1946038, 2085727, 2272645, 2713089, 2744396, 7681002, 7694769, 8054599, 8118482, 8152336, 8474621, 8707372, 12126870, 12536054, 16573711, 20113637, 22661180, 22801414	KA, PTZ, Electro, AUD, Kin, other
Nimodipine	Subarachnoid haemorrhage	1628595, 1698518, 2272645, 2310938, 2463174, 2662221, 3784769, 7681002, 8152336, 8156970, 8156971, 8707372, 9389584, 9570719, 9689485, 10683952, 12372903, 12536054, 12539272, 15123017, 17193898, 17344939, 19761108, 23761887, 25225705, 25445375	KA, Pilo, PTZ, Electro, AUD, Kin, other
Orphenadrine	Parkinsonism	2624511, 19815957	PTZ, Electro
Pimozide	Schizophrenia	2272645, 6141554, 7875556	PTZ, Electro, AUD, other
Pioglitazone	Diabetes mellitus	20599832, 22436324, 27527983	PTZ, other
Quetiapine	Schizophrenia; mania; depression	21168466, 26188240	PTZ, AUD
Tamoxifen	Breast cancer; anovulatory infertility	12139106, 24903749	Electro, Kin
Thalidomide	Malignant disease; immunosuppression	17449064, 21592729, 24735834	PTZ, Kin

Supplementary table 9. Genetic correlations between our main GWAS and Biobank GWAS (including deCODE genetics). P-values are shown, with standard errors in brackets.

	Primary All epilepsy	Primary Focal	Primary GGE
Biobank All epilepsy	0.74 (0.106)	0.5525 (0.1781)	0.7036 (0.0879)
Biobank Focal	0.5835 (0.1596)	0.7637 (0.2505)	0.4331 (0.1275)
Biobank Gen	0.6231 (0.1434)	0.307 (0.2176)	0.6521 (0.1373)

Supplementary table 10. Sample sizes of the included Biobanks and deCODE genetics.

Cohort	All epilepsy	Focal	GGE	Controls
UK Biobank	7,006	-	-	179,763
Japan Biobank	612	145	283	176,694
DECODE genetics	3,762	405	1,342	335,389
FinnGen	10,354	5,922	1,160	332,143
Total	21,734	6,472	2,785	1,023,989

Supplementary table 11. Phenotypes and associated publications assessed for genetic correlations with epilepsy using LDSC.

Broad trait	Trait	Publication	Notes
Psychiatric	Bipolar disorder	Mullins <i>et al</i> 2021 <sup>2</sup>	
Psychiatric	ADHD	Demontis <i>et al</i> 2019 <sup>3</sup>	
Psychiatric	ASD	Grove <i>et al</i> 2019 <sup>4</sup>	
Psychiatric	Schizophrenia	Trubetskoy <i>et al</i> 2022 <sup>5</sup>	
Psychiatric	Depression	Howard <i>et al</i> 2019 <sup>6</sup>	exc. UKBB and 23andMe
Neurological	Febrile seizures	Skotte <i>et al</i> 2022 <sup>7</sup>	
Neurological	Parkinson's disease	Nalls et al 2019 <sup>8</sup>	exc. 23andMe
Neurological	Alzheimer's disease	Wightman <i>et al</i> 2021 <sup>9</sup>	exc. 23andMe
Neurological	Stroke	Malik <i>et al</i> 2018 <sup>10</sup>	
Neurological	Headache	Meng <i>et al</i> 2018 <sup>11</sup>	
Neurological / Autoimmune	Multiple sclerosis	International Multiple Sclerosis Genetics Consortium 2019 <sup>12</sup>	
Autoimmune	Type 1 diabetes	Chiou <i>et al</i> 2021 <sup>13</sup>	
Autoimmune	Systemic lupus erythematosus	Morris <i>et al</i> 2016 <sup>14</sup>	
Cognitive	Intelligence	Savage, Jansen <i>et al</i> 2018 <sup>15</sup>	
Sleep	Insomnia	Jansen <i>et al</i> 2019 <sup>16</sup>	exc. 23andMe
Smoking	Ever smoked	Karlsson Linnér <i>et al</i> 2019 <sup>17</sup>	
Metabolic	Type 2 diabetes	Mahajan <i>et al</i> 2018 <sup>18</sup>	
Metabolic	Coronary disease	van der Harst, Verweij <i>et al</i> 2018 <sup>19</sup>	

#### Supplementary Figures



Supplementary figure 1. Manhattan plots of epilepsy subphenotype GWAS. Chromosomal position is plotted on the X-axis and -log10 transformed P-values are plotted on the Y-axis. A. juvenile myoclonic epilepsy (JME); B. childhood absence epilepsy (CAE); C. juvenile absence epilepsy (JAE); D. generalized tonic-clonic seizures alone (GTCS); E. focal epilepsy due to hippocampal sclerosis (focal HS); F. focal epilepsy with other lesion; G. lesion negative focal epilepsy.



Supplementary figure 2. 3D chromatin interactions link the 2p16.1 locus with the promoter region of BCL11A. The upper circus plot shows the 2p16.1 locus with GWAS P-values in the outer ring, with eQTL associations in green and HiC 3D chromatin interactions in orange. The locuszoom below shows GWAS P-values with chromatin states and Hi-C chromatin interactions below.



Supplementary figure 3. Manhattan plots of HLA analysis for A) All Epilepsy, B) Focal Epilepsy, C) GGE, D) JME, E) Focal lesion negative, F) Focal due to other lesion, G) Focal HS.



Supplementary figure 4. Power analysis for GGE, using the MiXeR causal mixture model.<sup>20</sup> The X-axis shows the current and required sample size, and the Y-axis shows the corresponding explained variance by genome-wide significant SNPs at these sample sizes. An explained variance of 100% corresponds to the identification of all SNPs that underlie GGE SNP-based heritability.



Supplementary figure 5. Heritability estimates and genetic correlations between epilepsy syndromes. The genetic correlation coefficient was calculated with LDSC and is denoted by color scale from -1 (red) to +1 (blue). # rg out of bounds due to phenotype not reaching significant heritability; \* P < 0.05, \*\* P < 0.0024 (Bonferroni correction).



Supplementary figure 6. Tissue-type enrichment of broad tissue types, as calculated with MAGMA,<sup>21</sup> using data from the Gene-Tissue Expression consortium (GTEx). The dotted line represents the significance threshold.



Supplementary figure 7. Tissue-type enrichment of 54 tissues, including specific brain regions, as calculated with MAGMA<sup>21</sup> using data from GTEx. The dotted line represents the significance threshold.



Supplementary figure 8. Enrichment of genes expressed in the brain at 11 general developmental stages, as calculated with MAGMA,<sup>21</sup> using data from the BrainSpan consortium. The dotted line represents the significance threshold.



Supplementary figure 9. Cell-type enrichment analyses across datasets, as calculated with FUMA.<sup>22</sup> Two different single-cell RNA sequencing datasets of human adult and developmental brain cells were assessed. Results from individual datasets are displayed in A-D with significant associations (after FDR correction) in red. Significant cell types across datasets are displayed in E, and significant cell-types after within dataset conditional analyses are displayed in F. Ex: excitatory neuron; In: inhibitory neuron.



Supplementary figure 10. Sex-specific GWAS of all epilepsy. The female-only is displayed at the top (n=13889 cases and 19676 controls) and male-only GWAS is displayed at the bottom (n=12259 cases and 18645 controls). We annotated genes that were implicated by our gene prioritization analyses.



Supplementary figure 11. Sex-specific GWAS of focal epilepsy. The female-only is displayed at the top (n=7175 cases and 19676 controls) and male-only GWAS is displayed at the bottom (n=6756 cases and 18645 controls).



Supplementary figure 12. Sex-specific GWAS of GGE. The female-only is displayed at the top (n=3946 cases and 19676 controls) and male-only GWAS is displayed at the bottom (n=2603 cases and 18645 controls). We annotated genes that were implicated by our gene prioritization analyses.



Epilepsy genome-wide significant loci

Supplementary figure 13. GWAS traits each of the epilepsy genome-wide significant loci have been associated with indicated by a purple cell. Prior trait associations were determined by a p < 5\*10-8 GWAS Catalog entry for the same SNP, or SNPs in high LD, as those reported in the epilepsy analysis.



Supplementary figure 14. Bivariate MiXeR analyses<sup>20</sup> showing the fraction of causal SNPs that are unique to GGE (blue), and shared (grey) and unique to ASD (left) or intelligence (right). Rg: genetic correlation coefficient.



Supplementary figure 15. Manhattan plots of Biobank-only GWAS of all (A), focal (B) and GGE (C). Chromosomal position is plotted on the X-axis and -log10 transformed P-values are plotted on the Y-axis.



Supplementary figure 16. Manhattan plots of meta-analysis combining the Biobanks with our primary GWAS of all (A), focal (B) and GGE (C). Chromosomal position is plotted on the X-axis and -log10 transformed P-values are plotted on the Y-axis.



Supplementary figure 17. Gene co-expression matrix produced by brain-coX<sup>23</sup> for known (grey) and candidate (black) epilepsy genes.

#### Supplementary References

1. International League Against Epilepsy Consortium on Complex Epilepsies. Genome-wide mega-analysis identifies 16 loci and highlights diverse biological mechanisms in the common epilepsies. Nat Commun 2018;9:5269.

2. Mullins N, Forstner AJ, O'Connell KS, et al. Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology. Nat Genet 2021;53:817-829.

3. Demontis D, Walters RK, Martin J, et al. Discovery of the first genome-wide significant risk loci for attention deficit/hyperactivity disorder. Nat Genet 2019;51:63-75.

4. Grove J, Ripke S, Als TD, et al. Identification of common genetic risk variants for autism spectrum disorder. Nat Genet 2019;51:431-444.

5. Trubetskoy V, Pardinas AF, Qi T, et al. Mapping genomic loci implicates genes and synaptic biology in schizophrenia. Nature 2022;604:502-508.

6. Howard DM, Adams MJ, Clarke TK, et al. Genome-wide meta-analysis of depression identifies 102 independent variants and highlights the importance of the prefrontal brain regions. Nat Neurosci 2019;22:343-352.

7. Skotte L, Fadista J, Bybjerg-Grauholm J, et al. Genome-wide association study of febrile seizures implicates fever response and neuronal excitability genes. Brain 2022;145:555-568.

8. Nalls MA, Blauwendraat C, Vallerga CL, et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet Neurol 2019;18:1091-1102.

9. Wightman DP, Jansen IE, Savage JE, et al. A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer's disease. Nat Genet 2021;53:1276-1282.

10. Malik R, Chauhan G, Traylor M, et al. Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes. Nat Genet 2018;50:524-537.

11. Meng W, Adams MJ, Hebert HL, Deary IJ, McIntosh AM, Smith BH. A Genome-Wide Association Study Finds Genetic Associations with Broadly-Defined Headache in UK Biobank (N=223,773). EBioMedicine 2018;28:180-186.

12. International Multiple Sclerosis Genetics Consortium. Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science 2019;365.

13. Chiou J, Geusz RJ, Okino ML, et al. Interpreting type 1 diabetes risk with genetics and single-cell epigenomics. Nature 2021;594:398-402.

14. Morris DL, Sheng Y, Zhang Y, et al. Genome-wide association meta-analysis in Chinese and European individuals identifies ten new loci associated with systemic lupus erythematosus. Nat Genet 2016;48:940-946.

15. Savage JE, Jansen PR, Stringer S, et al. Genome-wide association meta-analysis in 269,867 individuals identifies new genetic and functional links to intelligence. Nat Genet 2018;50:912-919.

16. Jansen PR, Watanabe K, Stringer S, et al. Genome-wide analysis of insomnia in 1,331,010 individuals identifies new risk loci and functional pathways. Nat Genet 2019;51:394-403.

17. Karlsson Linner R, Biroli P, Kong E, et al. Genome-wide association analyses of risk tolerance and risky behaviors in over 1 million individuals identify hundreds of loci and shared genetic influences. Nat Genet 2019;51:245-257.

18. Mahajan A, Taliun D, Thurner M, et al. Fine-mapping type 2 diabetes loci to single-variant resolution using high-density imputation and islet-specific epigenome maps. Nat Genet 2018;50:1505-1513.

19. van der Harst P, Verweij N. Identification of 64 Novel Genetic Loci Provides an Expanded View on the Genetic Architecture of Coronary Artery Disease. Circ Res 2018;122:433-443.

20. Frei O, Holland D, Smeland OB, et al. Bivariate causal mixture model quantifies polygenic overlap between complex traits beyond genetic correlation. Nat Commun 2019;10:2417.

21. de Leeuw CA, Mooij JM, Heskes T, Posthuma D. MAGMA: generalized gene-set analysis of GWAS data. PLoS Comput Biol 2015;11:e1004219.

22. Watanabe K, Taskesen E, van Bochoven A, Posthuma D. Functional mapping and annotation of genetic associations with FUMA. Nat Commun 2017;8:1826.

23. Freytag S, Burgess R, Oliver KL, Bahlo M. brain-coX: investigating and visualising gene coexpression in seven human brain transcriptomic datasets. Genome Med 2017;9:55.